Herpes Simplex Encephalitis Treated with Systemic 5-Iodo-2′deoxyuridine
- 1 November 1966
- journal article
- research article
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 65 (5), 1050-1056
- https://doi.org/10.7326/0003-4819-65-5-1050
Abstract
Acute necrotizing encephalitis due to herpes simplex virus can be a fatal or severely debilitating disease (1-4). The outlook is especially poor in those patients in whom the disease progresses to coma and convulsions (1, 2). An analogue of thymidine, 5-iodo-2′deoxyuridine (IUDR), inhibits the growth of herpes simplex and other deoxyribonucleic acid (DNA) viruses in vitro (5, 6) and has been used topically in the treatment of herpes simplex keratitis (7, 8). It has been suggested that systemic IUDR might be helpful in slowing or aborting the progression of potentially lethal systemic viral diseases such as herpes simplex encephalitis (7,Keywords
This publication has 4 references indexed in Scilit:
- Herpes Simplex EncephalitisAnnals of Internal Medicine, 1966
- Encephalitis Associated with Herpes Simplex VirusAnnals of Internal Medicine, 1966
- Inhibition by Metabolic Analogues of Plaque Formation by Herpes Zoster and Herpes Simplex VirusesThe Journal of Immunology, 1964
- Encephalitis associated with herpes simplex infection presenting as a temporal‐lobe massNeurology, 1964